Article
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
Cold Spring Harbor molecular case studies - 1 Feb 2021
Pandya Deep, Shah Myra, Kaplan Fuat, Martino Candice, Levy Gillian, Kazanjian Mia, Batter Stephen, Martignetti John, Frank Richard C
Abstract excerpt
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its incidence is expected to increase as castration-resistant disease emerges from the widespread use of potent androgen receptor-targeting therapies, such as abiraterone and enzalutamide. Defects in homologous recombination repair genes, such as BRCA1/2, are also being increasingly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.